Pretreatment of ADSCs with resveratrol-functionalized selenium nanoparticles alleviate CCl 4 -induced liver fibrosis in mice.
Liu S., Zhang Z., Luo D., Wen F., Zhu X., Chen X.
Animal Study, published in Biochim Biophys Acta Mol Basis Dis (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Biochim Biophys Acta Mol Basis Dis (2026)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42142461
- DOI
- 10.1016/j.bbadis.2026.168290
Abstract (original English)
Background Liver fibrosis (LF) is an abnormal repair reaction after chronic liver injury. Currently, adipose-derived mesenchymal stem cells (ADSCs) are widely used in the treatment of liver diseases. However, the therapeutic effect of ADSCs is affected by the damaged microenvironment. In this study, a resveratrol-functionalized nano‑selenium (Res@SeNPs) formulation was prepared to investigate whether Res@SeNPs pretreatment can enhance the therapeutic effect and alter the potential mechanism of ADSCs in carbon tetrachloride (CCl 4 ) -induced LF in mice. Methods Res@SeNPs were prepared and ADSCs pretreated with Res@SeNPs were cocultured with CCl 4 -injured BRL-3A cells in vitro. In vivo, ADSCs pretreated with Res@SeNPs were injected into the tail vein of a CCl 4 -induced LF mouse model. Results Res@SeNPs were successfully prepared. In vitro, after coculture with BRL-3A cells, the function of damaged BRL-3A cells was improved. In vivo, Res@SeNPs-pretreated ADSCs effectively alleviated liver function damage and fibrosis in mice with LF. This may be related to the inhibition of oxidative stress, the reduction in apoptosis and the inhibition of the activation of the apoptosis signal-regulated kinase 1/c-Jun N-terminal kinase/p38 mitogen-activated protein kinase (ASK1/JNK/p38) pathway. Conclusion Our study suggested that Res@SeNPs pretreatment can enhance the therapeutic effect of ADS
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.